Your browser doesn't support javascript.
loading
Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma.
Patiño-García, Ana; Guruceaga, Elizabeth; Andueza, Maria Pilar; Ocón, Marimar; Fodop Sokoudjou, Jafait Junior; de Villalonga Zornoza, Nicolás; Alkorta-Aranburu, Gorka; Uria, Ibon Tamayo; Gurpide, Alfonso; Camps, Carlos; Jantus-Lewintre, Eloísa; Navamuel-Andueza, Maria; Sanmamed, Miguel F; Melero, Ignacio; Elgendy, Mohamed; Fusco, Juan Pablo; Zulueta, Javier J; de-Torres, Juan P; Bastarrika, Gorka; Seijo, Luis; Pio, Ruben; Montuenga, Luis M; Hernáez, Mikel; Ochoa, Idoia; Perez-Gracia, Jose Luis.
Afiliación
  • Patiño-García A; Department of Pediatrics and Clinical Genetics, Clínica Universidad de Navarra (CUN), Cancer Center Clínica Universidad de Navarra (CCUN), Program in Solid Tumors, Center for Applied Medical Research (Cima) and Navarra Institute for Health Research (IdisNA), University of Navarra, Pamplona, Spain.
  • Guruceaga E; Bioinformatics Platform, Cima and IdisNA, University of Navarra, Pamplona, Spain.
  • Andueza MP; Department of Oncology, CUN, CCUN and IdisNA, University of Navarra, Pamplona, Spain.
  • Ocón M; Pulmonary Department, CUN, CCUN and IdisNA, University of Navarra, Pamplona, Spain.
  • Fodop Sokoudjou JJ; Electrical and Electronic Engineering Department, Tecnun, University of Navarra, San Sebastian, Spain.
  • de Villalonga Zornoza N; Electrical and Electronic Engineering Department, Tecnun, University of Navarra, San Sebastian, Spain.
  • Alkorta-Aranburu G; CIMA LAB Diagnostics and IdisNA, University of Navarra, Pamplona, Spain.
  • Uria IT; Bioinformatics Platform, Cima and IdisNA, University of Navarra, Pamplona, Spain.
  • Gurpide A; Department of Oncology, CUN, CCUN and IdisNA, University of Navarra, Pamplona, Spain.
  • Camps C; Department of Medical Oncology, Hospital General Universitario de Valencia, Unidad Mixta TRIAL (Fundación para la Investigación del Hospital General Universitario de Valencia y Centro de Investigación Príncipe Felipe) and Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Valencia, Spain.
  • Jantus-Lewintre E; Department of Biotechnology, Universitat Politècnica de València, Unidad Mixta TRIAL (Fundación para la Investigación del Hospital General Universitario de Valencia y Centro de Investigación Príncipe Felipe) and CIBERONC, Valencia, Spain.
  • Navamuel-Andueza M; Pulmonary Department, CUN, CCUN and IdisNA, University of Navarra, Pamplona, Spain.
  • Sanmamed MF; Department of Oncology, CUN, Division of Immunology, Cima, CCUN, IdisNA and CIBERONC, University of Navarra, Pamplona, Spain.
  • Melero I; Division of Immunology, Cima and Immunotherapy, CUN, CCUN, IdisNA and CIBERONC, University of Navarra, Pamplona, Spain.
  • Elgendy M; Institute for Clinical Chemistry and Laboratory Medicine, Mildred-Scheel Early Career Center, National Center for Tumor Diseases Dresden (NCT/UCC), University Hospital and Faculty of Medicine, Medical Clinic I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Fusco JP; Department of Medical Oncology Hospital La Luz, Quirón, Madrid, Spain.
  • Zulueta JJ; Pulmonary, Critical Care, and Sleep Division, Mount Sinai Morningside Hospital, New York, USA.
  • de-Torres JP; Pulmonary Department, CUN, CCUN and IdisNA, University of Navarra, Pamplona, Spain.
  • Bastarrika G; Department of Radiology, CUN, CCUN and IdisNA, Pamplona, Spain.
  • Seijo L; Pulmonary Department, CUN, CCUN and Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), University of Navarra, Madrid, Spain.
  • Pio R; Program in Solid Tumors, Cima -CCUN, Department of Biochemistry and Genetics, School of Science, IdisNA and CIBERONC, University of Navarra, Pamplona, Spain.
  • Montuenga LM; Program in Solid Tumors, Cima, Department of Pathology, Anatomy and Physiology, Schools of Medicine and Sciences, CCUN, IdisNA and CIBERONC, University of Navarra, Pamplona, Spain.
  • Hernáez M; Computational Biology Program, Cima, Data Science and Artificial Intelligence Institute (DATAI), CCUN, IdisNA and CIBERONC, University of Navarra, Pamplona, Spain.
  • Ochoa I; Electrical and Electronic Engineering Department, Tecnun, DATAI, University of Navarra, San Sebastian, Spain.
  • Perez-Gracia JL; Department of Oncology, CUN, CCUN, IdisNA and CIBERONC, University of Navarra, Pamplona, Spain. Electronic address: jlgracia@unav.es.
EBioMedicine ; 102: 105048, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38484556
ABSTRACT

BACKGROUND:

Tobacco is the main risk factor for developing lung cancer. Yet, while some heavy smokers develop lung cancer at a young age, other heavy smokers never develop it, even at an advanced age, suggesting a remarkable variability in the individual susceptibility to the carcinogenic effects of tobacco. We characterized the germline profile of subjects presenting these extreme phenotypes with Whole Exome Sequencing (WES) and Machine Learning (ML).

METHODS:

We sequenced germline DNA from heavy smokers who either developed lung adenocarcinoma at an early age (extreme cases) or who did not develop lung cancer at an advanced age (extreme controls), selected from databases including over 6600 subjects. We selected individual coding genetic variants and variant-rich genes showing a significantly different distribution between extreme cases and controls. We validated the results from our discovery cohort, in which we analysed by WES extreme cases and controls presenting similar phenotypes. We developed ML models using both cohorts.

FINDINGS:

Mean age for extreme cases and controls was 50.7 and 79.1 years respectively, and mean tobacco consumption was 34.6 and 62.3 pack-years. We validated 16 individual variants and 33 variant-rich genes. The gene harbouring the most validated variants was HLA-A in extreme controls (4 variants in the discovery cohort, p = 3.46E-07; and 4 in the validation cohort, p = 1.67E-06). We trained ML models using as input the 16 individual variants in the discovery cohort and tested them on the validation cohort, obtaining an accuracy of 76.5% and an AUC-ROC of 83.6%. Functions of validated genes included candidate oncogenes, tumour-suppressors, DNA repair, HLA-mediated antigen presentation and regulation of proliferation, apoptosis, inflammation and immune response.

INTERPRETATION:

Individuals presenting extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma show different germline profiles. Our strategy may allow the identification of high-risk subjects and the development of new therapeutic approaches.

FUNDING:

See a detailed list of funding bodies in the Acknowledgements section at the end of the manuscript.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Adenocarcinoma del Pulmón / Neoplasias Pulmonares Límite: Aged / Humans / Middle aged Idioma: En Revista: EBioMedicine Año: 2024 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Adenocarcinoma del Pulmón / Neoplasias Pulmonares Límite: Aged / Humans / Middle aged Idioma: En Revista: EBioMedicine Año: 2024 Tipo del documento: Article País de afiliación: España